Pfizer-BioNTech's Covid-19 vaccine deliveries may start before Christmas


By Michael Erman and Ludwig Burger (Reuters) - Pfizer Inc and BioNTech <22UAy.DE> could secure emergency U.S.

and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday. The vaccine's efficacy was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately hurt the elderly and certain groups including Black people.   Tracking.

This article is no longer available in our repository.

There could be multiple reasons for this.